Sudeepa Syamala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sudeepa Syamala has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
95 shared publications - Massimo Loda
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, USA
52 shared publications - Giorgia Zadra
Institute of Molecular Genetics, National Research Council, Pavia, Italy
51 shared publications - Paolo Chetta
University of Milan, Milan, Italy
51 shared publications - Daniel Eidelberg Spratt
University Hospitals Cleveland Medical Center 20 Cleveland, OH
50 shared publications - David P. Labbé
Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
50 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (2)
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
Small cell lung cancer (SCLC) transformation is an incompletely characterized mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR -mutant cancers, limiting development of optimal treatment approaches. Through single-cell RNA sequencing of malignant pleural effusions from patients who underwent SCLC transformation, we identified heterogeneity and diversity, including distinct neuroendocrine (NE) and mesenchymal non-NE cancer cell subsets, which were maintained in patient-derived cell lines. We demonstrate that EZH2 regulates EGFR expression in NE cells where EGFR expression is silenced at baseline. Although neither epigenetic derepression nor exogenous overexpression of mutant EGFR sensitized the cells to EGFR inhibition, non-NE cells exhibited selective sensitivity to MEK inhibitors. Combined MEK inhibitor and chemotherapy effectively inhibited growth of both NE and non-NE cells in vitro and in vivo. Our findings demonstrate that EGFR -mutant SCLC is composed of mixed cell states with distinct therapeutic vulnerabilities and offer a therapeutic strategy to target tumor heterogeneity in highly plastic and treatment-resistant malignancies such as transformed SCLC.
- 23 January 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (2)
Open AccessEGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
Small cell lung cancer (SCLC) transformation is an incompletely characterized mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR -mutant cancers, limiting development of optimal treatment approaches. Through single-cell RNA sequencing of malignant pleural effusions from patients who underwent SCLC transformation, we identified heterogeneity and diversity, including distinct neuroendocrine (NE) and mesenchymal non-NE cancer cell subsets, which were maintained in patient-derived cell lines. We demonstrate that EZH2 regulates EGFR expression in NE cells where EGFR expression is silenced at baseline. Although neither epigenetic derepression nor exogenous overexpression of mutant EGFR sensitized the cells to EGFR inhibition, non-NE cells exhibited selective sensitivity to MEK inhibitors. Combined MEK inhibitor and chemotherapy effectively inhibited growth of both NE and non-NE cells in vitro and in vivo. Our findings demonstrate that EGFR -mutant SCLC is composed of mixed cell states with distinct therapeutic vulnerabilities and offer a therapeutic strategy to target tumor heterogeneity in highly plastic and treatment-resistant malignancies such as transformed SCLC.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S7. Sequences of Alt-R CRISPR-Cas9 sgRNAs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S7. Sequences of Alt-R CRISPR-Cas9 sgRNAs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S11 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S11: Cyclin D1 Kinase Activity is Dispensable for Cyclin D1 to Confer HIF2alpha-Independence in the Cells Lacking All 3 pRB Paralogs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S11 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S11: Cyclin D1 Kinase Activity is Dispensable for Cyclin D1 to Confer HIF2alpha-Independence in the Cells Lacking All 3 pRB Paralogs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S3. Sequences of Oligonucleotides Used for the Cloning of CRISPRa and CRISPRko sgRNAs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S3. Sequences of Oligonucleotides Used for the Cloning of CRISPRa and CRISPRko sgRNAs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S7: The HIF2 Inhibitor PT2399 Impairs G1/S Traversal by ccRCC Cells
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S7: The HIF2 Inhibitor PT2399 Impairs G1/S Traversal by ccRCC Cells
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S8: HIF2alpha Inhibitor PT2399 Does Not Induce Apoptosis in ccRCC Cell Lines
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S8: HIF2alpha Inhibitor PT2399 Does Not Induce Apoptosis in ccRCC Cell Lines
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S2. STR Profile Analysis of TUHR14TKB Cell Line
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S2. STR Profile Analysis of TUHR14TKB Cell Line
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S6 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S6: Cyclin D1 Kinase Activity is Required for Cyclin D1 to Confer HIF2alpha-Independence
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S6 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S6: Cyclin D1 Kinase Activity is Required for Cyclin D1 to Confer HIF2alpha-Independence
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S8. Sequences of Oligonucleotides Used to Determine the Efficiency of Cas9 Gene Editing at the RB1, RBL1, and RBL2 Loci
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S8. Sequences of Oligonucleotides Used to Determine the Efficiency of Cas9 Gene Editing at the RB1, RBL1, and RBL2 Loci
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S13 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S13: Sustained Expression of CCND1 Alone is Not Sufficient to Confer Resistance to PT2399 In Vivo
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S13 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S13: Sustained Expression of CCND1 Alone is Not Sufficient to Confer Resistance to PT2399 In Vivo